Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SOF+DCV

PreclinicalSmall molecule

HHumanity and Health Research Centre

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

HCV InfectionNot yet recruiting

HCV InfectionPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q2 2027

PreclinicalNot yet recruiting

HCV Infection

NCT07770984

Clinical

Trials by Indication[1]

Treatment1 trial

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients

Completed·HHumanity and Health Research Centre·Phase 4·NCT02482077·112 enrolled

HCV Infection1 trial

Clinical Study Evaluating the Optimal Drug Therapy in Chronic Kidney Disease Patients With HCV

Not yet recruiting·TTanta University·Preclinical·NCT07770984·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SOF+DCV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SOF+DCV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SOF+DCV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Humanity and Health Research Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHumanity and Health Research Centre

Related News